Text Size

The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01271764
First received: January 5, 2011
Last updated: September 25, 2012
Last verified: September 2012
History of Changes
  Purpose

Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.


Condition Intervention
Outcome of Endometrial Cancer
 Other: no drug

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • The role of G9a protein in endometrial cancer [ Time Frame: overall survial, disease-free survival ] [ Designated as safety issue: No ]
    We will correlate the G9a protein and outcome of endometrial cancer


Enrollment: 97
Study Start Date: January 2011
Study Completion Date: September 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: endometrial cancer Other: no drug
The role of G9a protein in patients with endometrial cancer

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all cases with endometrial cancer underwent staging operation

Exclusion Criteria:

  • nil
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01271764

Locations
Taiwan
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
Banqiao, New Taipei, Taiwan, 22050
Sponsors and Collaborators
Far Eastern Memorial Hospital
  More Information

No publications provided

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01271764     History of Changes
Other Study ID Numbers: 099095-E
Study First Received: January 5, 2011
Last Updated: September 25, 2012
Health Authority: Taiwan: Institutional Review Board

Additional relevant MeSH terms:
Endometrial Neoplasms
Sarcoma, Endometrial Stromal
Adenoma
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Uterine Diseases
Genital Diseases, Female
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Sarcoma
Neoplasms, Connective and Soft Tissue
Endometrial Stromal Tumors
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on May 16, 2013